At Alacrity Biosciences, we work hard to safeguard this valuable asset by developing innovative treatments for ophthalmic diseases that threaten vision and decrease quality of life. Specifically, our focus is on developing new treatments for ocular surface diseases, retinal disease and glaucoma.

Read more about our leading pharmaceutical development project: ALTY-0501.